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Abstract
Whether folic acid fortification and supplementation at the population level have led to a higher 
prevalence of vitamin B-12 deficiency in the absence of anemia remains to be examined among a 
nationally representative sample of older U.S. adults. We assessed the prevalence of low vitamin 
B-12 status in the absence of anemia or macrocytosis before and after fortification among adults 
aged >50 y using cross-sectional data from the NHANES 1991–1994 (prefortification) and 2001–
2006 (postfortification). We compared the prefortification and postfortification prevalence of 
multiple outcomes, including serum vitamin B-12 deficiency (<148 pmol/L) and marginal 
deficiency (148–258 pmol/L) with and without anemia (hemoglobin <130 g/L for men, <120 g/L 
for women) and with and without macrocytosis (mean cell volume >100 fL) using multinomial 
logistic regression, adjusting for age, sex, ethnicity, body mass index, C-reactive protein, and 
vitamin B-12 supplement use. Prefortification and postfortification serum vitamin B-12 deficiency 
without anemia [4.0 vs. 3.9%; adjusted prevalence ratio (aPR) (95% CI): 0.98 (0.67, 1.44)] or 
without macrocytosis [4.2 vs. 4.1%; aPR (95% CI): 0.96 (0.65, 1.43)] remained unchanged. 
Marginal deficiency without anemia [25.1 vs. 20.7%; aPR (95% CI): 0.82 (0.72, 0.95)] or without 
macrocytosis [25.9 vs. 21.3%; aPR (95%CI): 0.82 (0.72, 0.94)] were both significantly lower after 
fortification. After fortification, higher folic acid intake was associated with a lower prevalence of 
low serum B-12 status in the absence of anemia or macrocytosis. Results suggest that the 
prevalence of low serum B-12 status in the absence of anemia or macrocytosis among older U.S. 
adults did not increase after fortification. Thus, at the population level, we found no evidence to 
support concerns that folic acid adversely affected the clinical presentation of vitamin B-12 
deficiency among older adults.
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Before the discovery and isolation of vitamin B-12, the practices of consuming raw liver and 
liver extract injections were well-known, effective treatments for pernicious anemia (PA)6, a 
type of megaloblastic anemia—found mainly in older adults—characterized by macrocytosis 
and, if untreated, irreversible spinal cord damage (1). At the time, it was unknown that 
megaloblastic anemias could result from either folate or vitamin B-12 deficiency. Early 
reports of folic acid effectively correcting the megaloblastic anemia of pregnancy rapidly led 
to its use as a treatment for PA (2). In hindsight, this was a mistake because the underlying 
problem in PA results from vitamin B-12 deficiency. Anemia improved initially but relapsed 
eventually inmost patients with PA who were taken off liver therapy and placed on high-
dosage folic acid (3). Folic acid was also unable to effectively prevent or treat PA-associated 
neurologic complications (4,5).
The presence of neurologic complications in the absence of anemia among patients raised 
concerns that folic acid might have an adverse effect on vitamin B-12 deficiency. As 
reviewed previously, early case reports suggested that folic acid might directly cause 
neurologic damage or indirectly allow neurologic damage to progress without effective 
therapy by treating the anemia and making the underlying deficiency harder to detect (3,6). 
However, evidence of neuropathy in the absence of anemia among patients with PA who 
have not been treated with folic acid indicates that the appearance of neurologic 
complications without anemia could be unrelated to folic acid (7). Furthermore, in the early 
case reports, patients whose anemia improved after being administered folic acid could have 
had concurrent folate deficiency and thus responded to treatment (8).
Nevertheless, among countries that are considering or have introduced folic acid fortification 
for neural tube defects prevention, questions remain about whether exposure to higher levels 
of folic acid in fortified foods and supplements would affect the clinical presentation of 
vitamin B-12 deficiency, delay its diagnosis, and result in an increase in the proportion of 
individuals with low serum vitamin B-12 status in the absence of anemia or macrocytosis, in 
particular, among older adults who are more likely to have low vitamin B-12 status and 
higher folic acid intake than the rest of the population (9,10). Reviews of published scientific 
evidence indicate that amounts of folate (11–13) and folic acid (3) (i.e., <1 mg/d) typically 
consumed through diet or vitamin supplements are unlikely to be associated with neurologic 
complications in PA. However, several studies investigating the effects of folic acid 
fortification on the clinical presentation of vitamin B-12 deficiency have reported mixed 
findings (14–20). In the United States, the hematologic presentation of vitamin B-12 
deficiency after folic acid fortification remains to be assessed in a representative population 
of older adults. Defining low vitamin B-12 status often poses a challenge because of the lack 
of agreement regarding the most appropriate cutoffs and biomarker combinations, as well as 
the low specificity of clinical signs. Here, we examined the prevalence of low serum vitamin 
B-12 status in the absence of anemia or macrocytosis among older adults before and after 
mandatory folic acid fortification. Because an individual’s folate status could vary widely, 
6Abbreviations used: aPR, adjusted prevalence ratio; CRP, C-reactive protein; ECGP, enriched cereal grain product; MCV, mean cell 
volume; PA, pernicious anemia; RSE, relative standard error; RTE, ready-to-eat cereal; SUP, supplement containing folic acid.
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depending on the various different sources of folic acid consumed (10,21), we also stratified 
the analyses by the source and amount of folic acid from fortified foods and supplements to 
assess whether folic acid consumption patterns after fortification affected the hematologic 
presentation of vitamin B-12 deficiency.
Methods
Study design and population
NHANES are cross-sectional surveys conducted periodically from the 1960s to 1994 and 
continuously in 2-y cycles since 1999. Using nationally representative samples of non-
institutionalized civilians, NHANES monitor the health and nutritional status of the U.S. 
population. At the mobile examination center, survey participants gave informed consent, 
reported their health status and dietary intake, underwent physician-administered physical 
examinations, and provided blood samples for biomarker analyses. Survey protocols were 
approved by the National Center for Health Statistics Research Ethics Review Board. 
Additional details of the survey have been discussed previously (22).
To compare the prevalence of low vitamin B-12 status in the absence of anemia or 
macrocytosis before and after fortification, we used data from NHANES III Phase 2, 1991–
1994 (prefortification), the years for which serum vitamin B-12 measurements were 
available, and data combined from NHANES 2001–2002, 2003–2004, and 2005–2006 
(postfortification). To estimate the prevalence of low serum vitamin B-12 status in the 
absence of anemia or macrocytosis by source of folic acid intake and amount consumed 
from supplements, we used data from only postfortification years NHANES 2001–2006. 
Data from NHANES 1999–2000 were excluded from the analyses because folic acid intake 
was reported as part of the combined variable total folate intake (folic acid + natural food 
folate), and thus, its potential effects on the prevalence of low serum vitamin B-12 status in 
the absence of anemia or macrocytosis could not be assessed alone.
After limiting our analyses to adults aged >50 y, the initial sample size was 3614 before 
fortification and 6516 after fortification. To rule out other causes and factors potentially 
affecting anemia, we excluded participants who had liver disease (before: 115; after: 375), 
renal dysfunction (before: 195; after: 419), heavy alcohol use (before: 163; after: 316), or 
treatment for anemia <3 mo before survey participation (before: 115; after: 231) (23,24). 
Liver disease was defined as alanine aminotransferase >40 U/L (25). Renal disease was 
defined as serum creatinine >131 µmol/L for men and >115 µmol/L for women (26). Using 
the CDC definition, heavy alcohol use was defined as >2 drinks/d for men and >1 drink/d for 
women (27). Only participants with complete serum vitamin B-12, hemoglobin, and mean 
cell volume (MCV) measurements were included in the study. The final analytic sample size 
(and proportion of initial sample) was 2911 (80.5%) before fortification and 4946 (75.9%) 
after fortification.
Laboratory measurements
Hematologic indicators, B vitamins, and other biomarker analyses were performed on 
venous-blood and whole-blood hemolysate samples. Hemoglobin and MCV were measured 
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using the Coulter S-plus Jr in NHANES III Phase 2 and Coulter MAXM hematology flow 
cytometer in NHANES 2001–2006. Based on the WHO definition, anemia was defined as 
hemoglobin <130 g/L for men and <120 g/L for women (28). Macrocytosis was defined 
using the common clinical characterization of MCV >100 fL (24). Participants were 
categorized as being without anemia if their hemoglobin concentrations were above the 
cutoff (≥130 g/L for men and ≥120 g/L for women) and without macrocytosis if their MCV 
was ≤100 fL. Serum and RBC folate and serum vitamin B-12 concentrations were measured 
using the QuantaPhase II radioassay (Bio-Rad Laboratories). Normal serum vitamin B-12 
status was defined as serum B-12 >258 pmol/L. Low serum vitamin B-12 status was defined 
as 2 groups: 1) serum vitamin B-12 deficiency (<148 pmol/L); and 2) marginal deficiency 
(148–258 pmol/L) (29–31). Serum alanine aminotransferase and creatinine were measured 
as 1 of 22 analytes in a routine biochemistry profile analysis using the Hitachi multichannel 
analyzers in NHANES III Phase 2 (model 737) and NHANES 2001–2002 (model 704) and 
the Beckman Synchron LX20 in NHANES 2003–2006. Serum creatinine was determined 
using the Jaffe reaction across all years. As recommended by NHANES analytic guidelines, 
the Deming regression equation was applied to NHANES III, 2001–2002, and 2005–2006 to 
account for serum creatinine measurement error across survey years (32). C-reactive protein 
(CRP), an indicator of inflammation that might cause anemia by decreasing erythropoiesis, 
was quantified by latex-enhanced nephelometry on a Behring Nephelometer (33). Additional 
details on specimen processing and laboratory methods have been described previously (22).
Nutrient Intake
In the United States, folic acid can be found in fortified foods and dietary supplements. 
Among foods, enriched cereal grain products (ECGPs) are required to be fortified with 140 
µg of folic acid/100 g of flour, whereas ready-to-eat cereals (RTEs) can be voluntarily 
fortified up to 400 µg/serving (12,34). Supplements most commonly provide 400 µg of folic 
acid per pill. Vitamin B-12 can be found naturally in animal-source foods or synthetically 
added at variable amounts to supplements and fortified foods (e.g., RTEs) (35).
We estimated the total daily intake of folic acid and vitamin B-12 from foods and 
supplements for each participant using nutritional information from 24-h dietary recalls and 
data on supplement use. Detailed methods have been reported previously and are briefly 
described below (10). The daily amount of each nutrient consumed from foods was 
estimated using a single 24-h dietary recall in NHANES 2001–2002 and 2 separate 24-h 
dietary recalls in each of the 2-y cycles of NHANES 2003–2006. We estimated the average 
daily intake of folic acid or vitamin B-12 from supplements based on each participant’s use 
of dietary supplements containing either folic acid or vitamin B-12, respectively, within the 
previous 30 d. Total daily folic acid or vitamin B-12 intake was reported as micrograms per 
day and defined as the sum of the nutrient consumed (folic acid from fortified foods and 
vitamin B-12 from natural and synthetic sources) plus the average daily intake of the 
nutrient from supplements.
To examine whether the prevalence of low serum vitamin B-12 status in the absence of 
anemia or macrocytosis differed by folic acid intake from different sources, we divided the 
postfortification participants into 4 mutually exclusive folic acid intake groups. Individuals 
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who consumed ECGPs and no other foods fortified with folic acid were classified as ECGP 
only. Those who consumed ECGPs and RTEs but no supplements containing folic acid were 
classified as ECGP + RTE, and those who consumed ECGPs and supplements containing 
folic acid but no RTEs were classified as ECGP + SUP. Finally, those who consumed all 3 
sources were classified as ECGP + RTE + SUP. To examine whether the prevalence of low 
serum vitamin B-12 status in the absence of anemia or macrocytosis differed by the amount 
of folic acid consumed from supplements, we separated postfortification participants into 3 
categories by the amount of folic acid reportedly consumed daily from supplements: 0 µg/d 
(no supplements containing folic acid), 1–200 µg/d, and >200 µg/d.
Covariates
Covariates considered in the analyses included sex, age, race/ethnicity, BMI, smoking status, 
and CRP. Race/ethnicity was divided into 4 categories: 1) non-Hispanic whites; 2) non-
Hispanic blacks; 3) Mexican Americans; 4) and other. Smoking status, reported by the 
participants at the time of their interview, was defined as yes/no. CRP was dichotomized; 
abnormal was defined as >10 mg/L (36,37). Participant BMIs were calculated by dividing 
their measured weight (kilograms) by their height (square meters). Age and BMI were 
treated as continuous variables.
Statistical analyses
All statistical analyses, with the exception of the usual intakes of folic acid and vitamin B-12 
(discussed below), were performed using SAS-Callable SUDAAN (version 10; 2008, 
Research Triangle Institute) to account for the complex survey design of NHANES. Using 
multiple linear regression, we estimated geometric means (least squares means) and 95% 
CIs for serum and RBC folate and vitamin B-12 adjusting for age, sex, race/ethnicity, 
smoking status, and BMI. These biomarker concentrations were log-transformed to 
normalize their distributions. Statistically significant differences were evaluated using 
Satterthwaite-adjusted F tests for continuous variables and χ2 tests for categorical variables. 
To determine the prevalence of low serum vitamin B-12 status in the presence or absence of 
anemia or macrocytosis, we examined multiple outcomes each separated into mutually 
exclusive and exhaustive categories. In one model, the outcome was divided into five 
categories: 1) vitamin B-12 deficiency without anemia; 2) vitamin B-12 deficiency with 
anemia; 3) marginal deficiency without anemia; 4) marginal deficiency with anemia; and 5) 
normal serum vitamin B-12 status (including those with and without anemia). In a separate 
model, an analogous outcome was assessed for macrocytosis in place of anemia. 
Multinomial logistic regression (38) was used to estimate the prevalence (e.g., predictive 
margins), adjusted prevalence ratios (aPRs), and 95% CIs by fortification period, source of 
folic acid intake, and amount of folic acid consumption from supplements. Estimates were 
adjusted for age, sex, race/ethnicity, BMI, and CRP (as well as oral vitamin B-12 
supplement use in comparisons between prefortification and postfortification time periods). 
Statistical significance for all tests was established at α = 0.05. To account for differential 
nonresponse and noncoverage, as well as the oversampling of specific groups in survey 
design, appropriate samples weights were used for all analyses (39,40). Mobile examination 
center sample weights were used for comparisons between NHANES III Phase 2 and 
NHANES 2001–2006. Dietary subsample weights were used for prevalence estimates of low 
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vitamin B-12 status in the absence of anemia or macrocytosis in NHANES 2001–2006 by 
source of folic acid intake and amount of folic acid consumed from supplements. Estimates 
with relative standard errors (RSEs) ≥30% were considered statistically unreliable and were 
reported with a footnote for RSE = 30–39% and not reported at all for RSE ≥40%.
From the total daily folic acid and vitamin B-12 intake (described above, Nutrient intake), 
we estimated the usual daily intake of each nutrient using the Software for Intake 
Distribution Estimation (PC-SIDE version 1.02; Iowa State University, Ames, IA). As has 
been described previously (41,42), usual daily nutrient intake estimates require at least a 
subsample of participants to have 2 d of dietary recall to estimate both the within- and 
between-person variations. In our analytic sample, participants from NHANES 2001–2002 
provided nutrient intake information for only 1 d; however, most of the participants from 
NHANES 2003–2006 had 2 independent days of intake data, allowing us to estimate usual 
nutrient intake for the entire sample. Usual daily folic acid and vitamin B-12 intakes were 
estimated stratified by folic acid intake group (ECGP, ECGP + RTE, ECGP + SUP, ECGP + 
RTE + SUP) and folic acid supplement use (0, 1–200, and >200 µg/d) after adjusting for 
intake day and day of the week. SEEs were obtained using jackknife replicate weights 
calculated based on a combination of day 2 dietary weights for individuals with 2 d of 
dietary recall data and day 1 dietary weights for individuals with only 1 d of dietary recall 
data. Details of PC-SIDE methodology are have been described previously (41,42). 
Comparisons of usual daily intakes of folic acid and vitamin B-12 within folic acid intake 
and folic acid supplement use groups were made using z tests. Six comparisons were made 
across the 4 folic acid intake groups, and 3 comparisons were made across the 3 folic acid 
supplement use groups.
Results
Among participants aged >50 y, the prevalence of marginal serum vitamin B-12 deficiency 
was significantly lower after compared with before fortification (Table 1). We observed no 
significant differences in the prevalence of serum vitamin B-12 deficiency (P = 0.23). Both 
serum vitamin B-12 concentration and the use of supplements containing vitamin B-12 were 
significantly higher after fortification. Furthermore, as expected, serum and RBC folate 
concentrations were higher after fortification. No significant differences were observed in 
the prevalence of anemia or macrocytosis across fortification periods. Additional 
characteristics of the analytic sample are presented in Table 1.
Overall, we did not observe a higher prevalence of low serum vitamin B-12 status in the 
absence of anemia or macrocytosis among those aged >50 y after fortification when 
compared with before fortification (Fig. 1; Supplemental Table 1). The prevalence of serum 
vitamin B-12 deficiency without anemia remained the same (before: 4.0%; after: 3.9%; aPR: 
0.98; 95% CI: 0.67, 1.44), whereas the prevalence of marginal deficiency without anemia 
was significantly lower after fortification (before: 25.1%; after: 20.7%; aPR: 0.82; 95% CI: 
0.72, 0.95). Similarly, no difference in serum vitamin B-12 deficiency without macrocytosis 
was observed (before: 4.2%; after: 4.1%; aPR: 0.96; 95% CI: 0.65, 1.43), and the prevalence 
of marginal deficiency without macrocytosis was lower after fortification (before: 25.9%; 
after: 21.3%; aPR: 0.82; 95%CI: 0.72, 0.94). In addition, the prevalence of serum vitamin 
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B-12 deficiency and marginal deficiency with anemia did not differ significantly before and 
after fortification (Supplemental Table 1).
After fortification, as expected, usual daily folic acid intake was significantly higher as 
groups consumed more sources of folic acid (ECGP only > ECGP + RTE > ECGP + SUP > 
ECGP + RTE + SUP) and higher amounts of supplemental folic acid (0 > 1–200 > >200 
µg/d) (Table 2). Similarly, usual daily vitamin B-12 intake also increased among groups 
consuming more sources of folic acid and increasing amounts of supplemental folic acid. 
Almost all users of supplements containing folic acid also consumed supplements containing 
vitamin B-12 (≥97.0%; Table 2). Lower prevalence of serum vitamin B-12 deficiency and 
marginal deficiency were associated with the consumption of RTEs and/or SUP and with 
higher daily intake of folic acid from supplements (Table 2).
Analyses by source of folic acid intake in the postfortification period showed that consuming 
additional sources of folic acid was associated with a lower prevalence of serum vitamin 
B-12 deficiency in the absence of anemia (Fig. 2A; ECGP only: 5.4%; ECGP + RTE: 4.2%; 
ECGP + SUP: 2.1%; ECGP + RTE + SUP: 1.6%) or macrocytosis (Fig. 2A; ECGP only: 
5.6%; ECGP + RTE: 4.3%; ECGP + SUP: 2.1%; ECGP + RTE + SUP: 1.7%). Compared 
with the ECGP-only group, those consuming ECGP + RTE + SUP were ~70% less likely to 
have serum vitamin B-12 deficiency without anemia or without macrocytosis (P = 0.0001 for 
both). Analogous results were observed for serum vitamin B-12 marginal deficiency without 
anemia (Fig. 2A; ECGP only: 30.7%; ECGP + RTE: 22.9%; ECGP + SUP: 11.1%; ECGP + 
RTE + SUP: 9.4%) or without macrocytosis (Fig. 2A; ECGP only: 31.4%; ECGP + RTE: 
23.8%; ECGP + SUP: 11.1%; ECGP + RTE + SUP: 9.6%).
Analyses by folic acid supplement use showed that increasing consumption of supplemental 
folic acid after fortification was associated with a lower prevalence of serum vitamin B-12 
deficiency without anemia (Fig. 2B; 0 µg/d: 5.0%; 1–200 µg/d: 3.9%; >200 µg/d: 1.5%) or 
without macrocytosis (Fig. 2B; 0 µg/d: 5.2%; 1–200 µg/d: 4.0%; >200 µg/d: 1.5%). 
Compared with those who consumed no folic acid from supplements, those who consumed 
>200 µg/d folic acid from supplements had significantly lower prevalence of serum vitamin 
B-12 deficiency and marginal deficiency without anemia or without macrocytosis (P < 
0.0001). Likewise, similar results were observed for marginal deficiency without anemia 
(Fig. 2B; 0 µg/d: 28.2%; 1–200 µg/d: 15.0%; >200 µg/d: 9.5%) or without macrocytosis 
(Fig. 2B; 0 µg/d: 29.0%; 1–200 µg/d: 14.9%; >200 µg/d: 9.7%).
Discussion
Examining the hematologic presentation of serum vitamin B-12 deficiency before and after 
folic acid fortification is one way to evaluate the influence of fortification on those with low 
vitamin B-12 status. Our study is the first to assess this issue among nationally 
representative older U.S. adults. In our analyses of cross-sectional NHANES data, we found 
no evidence that the prevalence of serum vitamin B-12 deficiency or marginal deficiency in 
the absence of anemia or macrocytosis was higher after fortification compared with before 
fortification among older U.S. adults.
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Our results are in agreement with previous reports from both voluntary and mandatory 
fortification settings which found no changes in anemia indicators and no evidence of 
deteriorating vitamin B-12 status among those with improved folate status (16,17). Our 
analyses are also consistent with a U.S. Veterans Affairs hospital-based report which found 
no significant differences in the proportion of adults with low serum vitamin B-12 (<258 
pmol/L) without anemia from before to after fortification (14). Results from that report 
remained unchanged even after restricting the analyses to older adults (>60 y) or using a 
more conservative cutoff for low serum vitamin B-12 status (<150 pmol/L).
Our findings were not consistent with those from a different U.S. hospital-based study, in 
which the proportion of adults with low serum vitamin B-12 without macrocytosis were 
higher after fortification (18). However, differences in sampling and population 
characteristics might have accounted for much of the divergent findings between the 2 
studies. For example, whereas our study examined a nationally representative sample of 
adults aged >50 y, the hospital-based study examined a convenience sample of individuals 
(fortification period: before, n = 86; peri, n = 138; after, n = 409) with racial/ethnic 
distribution, age, and health profiles that potentially differ from the general population (18). 
Furthermore, due to the lack of blood folate data, an overall improvement in population 
folate status (i.e., lower folate deficiency anemia) could not be ruled out in that study to 
explain the MCV improvements from before to after fortification.
In our study, we also observed that postfortification participants with higher usual intakes of 
folic acid (i.e., ECGP + RTE, ECGP + SUP, and ECGP + RTE + SUP groups or 1–200 and 
>200 µg/d groups) were less likely to have low serum vitamin B-12 status without anemia or 
without macrocytosis when compared with those with lower folic acid intake (i.e., ECGP 
alone or no folic acid from supplements). Because most RTEs and supplements containing 
folic acid also have added vitamin B-12 (10,43), older adults who are able to absorb the 
vitamin normally would have a higher vitamin B-12 intake and better vitamin B-12 status 
from consuming these products. Consistent with previously published NHANES data (10), 
our findings confirm that, as folic acid intake increased among older adults, usual vitamin 
B-12 intake and vitamin B-12 supplement use also increased, and the prevalence of serum 
vitamin B-12 deficiency and marginal deficiency were lower. It should be noted that 
individuals with PA would be unable to obtain sufficient vitamin B-12 from the low dosages 
typically found in RTEs and supplements and thus would require high pharmacologic doses 
of the vitamin to achieve adequate vitamin B-12 status.
Major strengths of our study include the large sample size available for analysis and that it 
was nationally representative of the U.S. population aged >50 y. The vast amount of data 
collected by NHANES allowed us to adjust for potential confounders (i.e., vitamin B-12 
supplement use, markers for inflammation) and exclude from the analyses individuals with 
conditions (i.e., heavy alcohol use, liver disease) that could affect vitamin B-12, hemoglobin, 
and MCV values but were not ruled out in previous published analyses.
Several limitations should be considered when interpreting the results of our study. First, our 
analyses are based on comparisons of group-level cross-sectional data before and after 
fortification; thus, causal inferences with respect to changes in vitamin B-12 deficiency 
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status cannot be made at the level of the individual. However, because controlled trials with 
folic acid among vitamin B-12–deficient populations would be unethical, comparisons of 
population prevalence across time periods are a valuable resource for assessing the influence 
of fortification on vitamin B-12 status. A similar approach has been used to examine 
potential changes in vitamin B-12 status associated with mandatory folic acid fortification in 
smaller non-representative samples (14,17,18). Second, because anemia and macrocytosis 
could only be defined as concurrently occurring with, rather than resulting from, low serum 
vitamin B-12 status, some misclassification might have occurred, but the exclusion of 
individuals with heavy alcohol use, liver disease, renal disease, and recent treatment for 
anemia from our analyses would limit the misclassification based on these other causes of 
anemia or macrocytosis. It should be noted that, by excluding individuals with heavy alcohol 
use, we might have also excluded some at higher risk of PA attributable to gastric atrophy 
from chronic alcohol use. Third, we did not include cognitive/neurologic function data from 
NHANES as outcomes in our analyses because of their lack of sensitivity and specificity to 
vitamin B-12 deficiency. Fourth, using solely serum vitamin B-12 <148 pmol/L to define 
deficiency might not be adequate (44). A recent expert roundtable discussion on vitamin 
B-12 biomarkers in NHANES recommended that biochemical vitamin B-12 deficiency be 
defined using one biomarker that directly measures vitamin B-12 in blood (i.e., serum 
vitamin B-12 or holotranscobalamin) and one functional indicator (i.e., methylmalonic acid 
or total homocysteine) to minimize sensitivity/specificity issues with using any individual 
marker alone (45). However, the use of different cutoffs and their combinations resulted in 
widely different prevalence estimates of low vitamin B-12 status and suggested that “[t]he 
most appropriate cutoffs for assessing vitamin B-12 status when using NHANES data 
remain elusive” (46). The lack of a formal method to compare the different methylmalonic 
acid assays in NHANES III Phase 2 and NHANES 2001–2004 (not measured in 2005–2006) 
also precluded the use of this functional indicator in our analyses (47). Fifth, self-reported 
folic acid and vitamin B-12 intakes in the dietary recalls and supplement use data might 
differ from actual intakes and fail to show patterns of irregular supplement consumption. 
Sixth, the amount of folic acid and vitamin B-12 reported in the nutritional database might 
be different from the actual amount found in foods. Last, despite the large study sample, the 
sample sizes were still small among some subgroups, resulting in unstable estimates.
In conclusion, we examined the hematologic presentation of serum vitamin B-12 deficiency 
before and after folic acid fortification and found no evidence of a higher prevalence of 
serum vitamin B-12 deficiency or marginal deficiency in the absence of anemia or 
macrocytosis among nationally representative U.S. adults aged >50 y after mandatory folic 
acid fortification. In the time period after fortification, we did not observe a higher 
prevalence of serum vitamin B-12 deficiency or marginal deficiency in the absence of 
anemia or macrocytosis with higher folic acid intake from foods and supplements. Better 
serum vitamin B-12 status was seen among adults with higher folic acid intake, which might 
reasonably be explained by higher intakes of vitamin B-12 also found in fortified foods and 
supplements (10). Our findings provide reassurance and help assuage concerns that exposure 
to higher levels of folic acid in fortified foods and supplements would adversely affect the 
clinical presentation of vitamin B-12 deficiency at the population level and delay its 
diagnosis. More importantly, advancements in medical and laboratory technology have 
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allowed for the identification of vitamin B-12 deficiency specifically without having to rely 
solely on hematologic indices. The routine use of these diagnostic tools along with efforts to 
educate clinicians about the risk factors and varied clinical presentations of vitamin B-12 
deficiency will allow for the timely diagnosis and treatment of this condition and the 
prevention of complications related to untreated vitamin B-12 deficiency.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Prevalence of low serum vitamin B-12 status in the absence of anemia or macrocytosis 
among U.S. adults aged >50 y in NHANES before and after mandatory folic acid 
fortification. Bars denote 95% CIs. *P < 0.001 based on prevalence estimate differences in 
serum vitamin B-12 deficiency (<148 pmol/L) and marginal deficiency (148–258 pmol/L) 
without anemia (hemoglobin ≥ 130 g/L for men, ≥120 g/L for women) or without 
macrocytosis (MCV ≤ 100 fL) using multinomial logistic regression adjusted for age, sex, 
race/ethnicity, BMI, C-reactive protein, smoking, and oral vitamin B-12 supplement use. 
Participants with liver disease, renal dysfunction, heavy alcohol use, and treatment of 
anemia <3 mo before survey participation were excluded from the analyses. Analyses were 
weighted to account for the complex sampling design of NHANES. MCV, mean cell 
volume; Serum B-12 def + no anemia, serum vitamin B-12 <148 pmol/L without anemia; 
serum B-12 def + no macrocytosis, serum vitamin B-12 <148 pmol/L without macrocytosis; 
serum B-12 marg def + no anemia, serum vitamin B-12 of 148–258 pmol/L without anemia; 
serum B-12 def + no macrocytosis, serum vitamin B-12 of 148–258 pmol/L without 
macrocytosis.
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Postfortification prevalence of low serum vitamin B-12 status in the absence of anemia or 
macrocytosis among U.S. adults aged >50 y in NHANES by folic acid intake group (A) and 
folic acid supplement intake group (B). Bars denote 95% CIs. Estimates with RSEs ≥30% 
were considered statistically unreliable and were reported with a dagger for RSE = 30–39%. 
Values across folic acid intake groups and folic acid supplement intake groups are 
significantly different and marked by different superscript letters (a > b > c) at P < 0.04 
using multinomial logistic regression adjusting for age, race/ethnicity, BMI, and C-reactive 
protein. Participants with liver disease, renal dysfunction, heavy alcohol use, and treatment 
of anemia <3 mo before survey participation were excluded from the analyses. ECGP, 
enriched cereal grain product; RSE, relative standard error; RTE, ready-to-eat cereal; serum 
B-12 def + no anemia, serum vitamin B-12 <148 pmol/L without anemia; serum B-12 def + 
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no macrocytosis, serum vitamin B-12 <148 pmol/L without macrocytosis; serum B-12 marg 
def + no anemia, serum vitamin B-12 of 148–258 pmol/L without anemia; serum B-12 def + 
no macrocytosis, serum vitamin B-12 of 148–258 pmol/L without macrocytosis; SUP, 
supplement containing folic acid; 0 µg/d, non-users and users of supplements containing no 
folic acid.
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TABLE 1





n, unweighted 2911 4946
Age, y 65.4 ± 0.5 64.2 ± 0.3*
Female, % 55.8 (52.8, 58.7) 55.9 (54.4, 57.4)
Race/ethnicity, %
  White, non-Hispanic 81.4 (76.7, 85.3) 80.4 (76.5, 83.7)
  Black, non-Hispanic 8.1 (6.4, 10.2) 8.6 (6.8, 10.9)
  Mexican American 2.8 (2.1, 3.6) 3.7 (2.6, 5.3)
  Other 7.7 (4.9, 11.9) 7.3 (5.5, 9.5)
Low serum vitamin B-12 status,2 %
  Marginal deficiency 27.7 (24.6, 31.0) 20.9 (19.3, 22.5)**
  Deficiency 4.8 (3.6, 6.5) 3.8 (3.1, 4.8)
Serum vitamin B-12, pmol/L 310 (302, 318) 352 (344, 360)***
Vitamin B-12 supplement use, % 29.0 (26.1, 32.0) 41.0 (38.7, 43.5)***
Serum folate, nmol/L 16.0 (15.1, 16.9) 33.0 (32.2, 33.8)***
RBC folate, nmol/L 464 (440, 490) 696 (682, 710)***
Anemia,3% 5.2 (4.3, 6.4) 4.9 (4.1, 5.7)
Macrocytosis,4% 1.9 (1.3, 3.0) 2.5 (2.0, 3.1)
1
Values are percentages (95% CIs) or geometric means (95% CIs). Age is reported as mean ± SE. Analyses were weighted to account for the 
complex sampling design of NHANES and excluded participants with liver disease, renal dysfunction, heavy alcohol use, and treatment of anemia 
<3 mo before survey participation. Surveys were compared using χ2 test for categorical variables and Satterthwaite-adjusted F test for continuous 
variables adjusting for age, sex, race/ethnicity, smoking status, and BMI (variables being analyzed were not treated as a potential confounder for 
their own analyses). Different from before fortification, *P < 0.05, **P < 0.001, ***P < 0.0001.
2
Serum vitamin B-12 concentrations for marginal deficiency were defined as 148–258 pmol/L; deficiency was defined as <148 pmol/L.
3
Anemia was defined as hemoglobin <130 g/L for men and <120 g/L for women.
4
Macrocytosis was defined as mean corpuscular volume >100 fL.
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